Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy.
Decision-making
Gastric cancer
Machine learning
Neoadjuvant chemotherapy
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
06
11
2020
accepted:
29
03
2021
revised:
08
03
2021
pubmed:
29
4
2021
medline:
21
10
2021
entrez:
28
4
2021
Statut:
ppublish
Résumé
To develop and evaluate machine learning models using baseline and restaging computed tomography (CT) for predicting and early detecting pathological downstaging (pDS) with neoadjuvant chemotherapy in advanced gastric cancer (AGC). We collected 292 AGC patients who received neoadjuvant chemotherapy. They were classified into (a) primary cohort (206 patients with 3-4 cycles chemotherapy) for model development and internal validation, (b) testing cohort I (46 patients with 3-4 cycles chemotherapy) for evaluating models' predictive ability before and after the complete course, and (c) testing cohort II (n = 40) for model evaluation on its performance at early treatment. We extracted 1,231 radiomics features from venous phase CT at baseline and restaging. We selected radiomics models based on 28 cross-combination models and measured the areas under the curve (AUC). Our prediction radiomics (PR) model is designed to predict pDS outcomes using baseline CT. Detection radiomics (DR) model is applied to restaging CT for early pDS detection. PR model achieved promising outcomes in two testing cohorts (AUC 0.750, p = .009 and AUC 0.889, p = .000). DR model also showed a good predictive ability (AUC 0.922, p = .000 and AUC 0.850, p = .000), outperforming the commonly used RECIST method (NRI 39.5% and NRI 35.4%). Furthermore, the improved DR model with averaging outcome scores of PR and DR models showed boosted results in two testing cohorts (AUC 0.961, p = .000 and AUC 0.921, p = .000). CT-based radiomics models perform well on prediction and early detection tasks of pDS and can potentially assist surgical decision-making in AGC patients. • Baseline contrast-enhanced computed tomography (CECT)-based radiomics features were predictive of pathological downstaging, allowing accurate identification of non-responders before therapy. • Restaging CECT-based radiomics features were predictive to achieve pDS after and even at an early stage of neoadjuvant chemotherapy. • Combination of baseline and restaging CECT-based radiomics features was promising for early detection and preoperative evaluation of pathological downstaging of AGC.
Identifiants
pubmed: 33909133
doi: 10.1007/s00330-021-07962-2
pii: 10.1007/s00330-021-07962-2
pmc: PMC8523390
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8765-8774Subventions
Organisme : National Basic Research Program of China (973 Program)
ID : No.2014CB744504
Informations de copyright
© 2021. The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2019 Mar 1;30(3):431-438
pubmed: 30689702
Ann Surg Oncol. 2013 Jun;20(6):2016-22
pubmed: 23266583
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Cancer Imaging. 2013 May 30;13:212-27
pubmed: 23722535
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Front Neuroinform. 2013 Dec 30;7:45
pubmed: 24416015
Eur J Radiol. 2012 Nov;81(11):2953-60
pubmed: 22304982
Cancer. 1992 Nov 1;70(9):2239-45
pubmed: 1327491
Chin J Cancer Res. 2018 Aug;30(4):406-414
pubmed: 30210220
Cancer Chemother Pharmacol. 2014 Jun;73(6):1155-61
pubmed: 24748418
J Cancer Res Clin Oncol. 2018 Nov;144(11):2207-2218
pubmed: 30094537
Cancer. 2008 Jun;112(11):2368-76
pubmed: 18404697
Eur J Radiol. 2017 May;90:129-137
pubmed: 28583623
Biometrics. 2003 Dec;59(4):1089-98
pubmed: 14969489
Br J Cancer. 1996 Jan;73(1):61-4
pubmed: 8554985
Clin Cancer Res. 1997 Sep;3(9):1457-66
pubmed: 9815831
Gastric Cancer. 2013 Oct;16(4):543-8
pubmed: 23187880
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Cancer Res. 2017 Apr 1;77(7):1548-1552
pubmed: 28330928
Br J Surg. 2014 May;101(6):653-60
pubmed: 24668391